Karolinska Development AB
Overview
Karolinska Development AB is a Nordic life sciences investment company focused on identifying and investing in breakthrough medical innovations to create and grow companies that advance these assets into commercial products.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AnaCardio | Sep 2022 | Series A | Co-investor |
| Cellectricon | May 2004 | Series B | Lead |
| BOOST Pharma | Oct 2025 | Convertible Debt | Co-investor |
For institutional investors. Book with your work email.
Key People
John Ohd
Chief Scientific Officer
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Karolinska Development AB based?
Karolinska Development AB is headquartered in Solna, Sweden.
When was Karolinska Development AB founded?
Karolinska Development AB was founded in 2003.
How many portfolio companies does Karolinska Development AB have?
Karolinska Development AB has 4 portfolio companies in Caplight's dataset.
What are some companies in Karolinska Development AB's portfolio?
Portfolio companies visible on Caplight include AnaCardio, Cellectricon, BOOST Pharma.
What was Karolinska Development AB's most recent investment shown here?
Karolinska Development AB's most recent investment in this portfolio sample was in BOOST Pharma in 2025.
What sectors does Karolinska Development AB focus on?
Karolinska Development AB focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Consumer & Commerce.
What company stages does Karolinska Development AB focus on?
Karolinska Development AB typically invests at the Early stage.